JP2013544816A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013544816A5 JP2013544816A5 JP2013540054A JP2013540054A JP2013544816A5 JP 2013544816 A5 JP2013544816 A5 JP 2013544816A5 JP 2013540054 A JP2013540054 A JP 2013540054A JP 2013540054 A JP2013540054 A JP 2013540054A JP 2013544816 A5 JP2013544816 A5 JP 2013544816A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- disease
- mammal
- tlr7
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 229940127089 cytotoxic agent Drugs 0.000 claims 8
- 241000124008 Mammalia Species 0.000 claims 7
- 239000005557 antagonist Substances 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 108010041986 DNA Vaccines Proteins 0.000 claims 5
- 229940021995 DNA vaccine Drugs 0.000 claims 5
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims 5
- 108020000411 Toll-like receptor Proteins 0.000 claims 5
- 102000002689 Toll-like receptor Human genes 0.000 claims 5
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims 5
- 239000002671 adjuvant Substances 0.000 claims 4
- 239000013566 allergen Substances 0.000 claims 4
- 239000003242 anti bacterial agent Substances 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 239000000074 antisense oligonucleotide Substances 0.000 claims 4
- 238000012230 antisense oligonucleotides Methods 0.000 claims 4
- 239000002254 cytotoxic agent Substances 0.000 claims 4
- 238000001415 gene therapy Methods 0.000 claims 4
- 229940043355 kinase inhibitor Drugs 0.000 claims 4
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 229960005486 vaccine Drugs 0.000 claims 4
- 239000013598 vector Substances 0.000 claims 4
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 3
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims 3
- 102100033117 Toll-like receptor 9 Human genes 0.000 claims 3
- 229960004784 allergens Drugs 0.000 claims 3
- 229940088710 antibiotic agent Drugs 0.000 claims 3
- -1 antibodies Substances 0.000 claims 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 239000002336 ribonucleotide Substances 0.000 claims 3
- LUCHPKXVUGJYGU-UHFFFAOYSA-N 4-amino-1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidin-2-one Chemical compound O=C1N=C(N)C(C)=CN1C1OC(CO)C(O)C1 LUCHPKXVUGJYGU-UHFFFAOYSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- 108091028664 Ribonucleotide Proteins 0.000 claims 2
- 239000000443 aerosol Substances 0.000 claims 2
- 239000007933 dermal patch Substances 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003889 eye drop Substances 0.000 claims 2
- 229940012356 eye drops Drugs 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000002324 mouth wash Substances 0.000 claims 2
- 229940051866 mouthwash Drugs 0.000 claims 2
- 125000002652 ribonucleotide group Chemical group 0.000 claims 2
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 206010018691 Granuloma Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 1
- 208000000209 Isaacs syndrome Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010072359 Neuromyotonia Diseases 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 208000000594 bullous pemphigoid Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000002491 encephalomyelitis Diseases 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 208000002741 leukoplakia Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 206010039722 scoliosis Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41549410P | 2010-11-19 | 2010-11-19 | |
| US61/415,494 | 2010-11-19 | ||
| US201161511709P | 2011-07-26 | 2011-07-26 | |
| US61/511,709 | 2011-07-26 | ||
| PCT/US2011/061412 WO2012068470A2 (en) | 2010-11-19 | 2011-11-18 | Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013544816A JP2013544816A (ja) | 2013-12-19 |
| JP2013544816A5 true JP2013544816A5 (https=) | 2015-02-26 |
| JP5813778B2 JP5813778B2 (ja) | 2015-11-17 |
Family
ID=46064566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013540054A Expired - Fee Related JP5813778B2 (ja) | 2010-11-19 | 2011-11-18 | トール様受容体に基づく免疫反応を調節するための免疫調節オリゴヌクレオチド（ｉｒｏ）化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US8486908B2 (https=) |
| EP (2) | EP3213770B1 (https=) |
| JP (1) | JP5813778B2 (https=) |
| KR (2) | KR101985382B1 (https=) |
| CN (2) | CN107012149A (https=) |
| AU (4) | AU2011329668B2 (https=) |
| CA (1) | CA2817891C (https=) |
| ES (1) | ES2697606T3 (https=) |
| MX (1) | MX340363B (https=) |
| WO (1) | WO2012068470A2 (https=) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05013658A (es) * | 2003-06-11 | 2006-03-02 | Hybridon Inc | Oligonucleotidos inmunomoduladores estabilizados. |
| WO2011091065A2 (en) | 2010-01-19 | 2011-07-28 | Northwestern University | Synthetic nanostructures including nucleic acids and/or other entities |
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| RU2013120302A (ru) | 2010-10-01 | 2014-11-20 | Модерна Терапьютикс, Инк. | Сконструированные нуклеиновые кислоты и способы их применения |
| KR101985382B1 (ko) * | 2010-11-19 | 2019-06-03 | 이데라 파마슈티칼즈, 인코포레이티드 | 톨-유사 수용체 기반 면역 반응을 조절하기 위한 면역 조절 올리고뉴클레오타이드(ｉｒｏ) 화합물 |
| EP2691101A2 (en) | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| RU2648950C2 (ru) | 2011-10-03 | 2018-04-02 | Модерна Терапьютикс, Инк. | Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение |
| CN104114572A (zh) | 2011-12-16 | 2014-10-22 | 现代治疗公司 | 经修饰的核苷、核苷酸和核酸组合物 |
| AU2013243948A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| WO2014081507A1 (en) | 2012-11-26 | 2014-05-30 | Moderna Therapeutics, Inc. | Terminally modified rna |
| CN103880941B (zh) * | 2012-12-21 | 2016-02-10 | 苏州偲聚生物材料有限公司 | 多肽、包含该多肽的检测器件和检测试剂盒 |
| KR101898177B1 (ko) * | 2013-01-08 | 2018-09-12 | 이데라 파마슈티칼즈, 인코포레이티드 | 톨－유사 수용체 기반 면역 반응을 조절하기 위한 면역 조절 올리고누클레오티드 （ｉｒｏ） 화합물 |
| EP2754714A1 (en) * | 2013-01-14 | 2014-07-16 | Sarepta Therapeutics, Inc. | Inhibitory oligonucleotides and their use in therapy |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| CN104098671A (zh) * | 2013-04-03 | 2014-10-15 | 苏州偲聚生物材料有限公司 | 多肽、包含该多肽的检测器件和检测试剂盒 |
| CN104098681B (zh) * | 2013-04-03 | 2016-08-10 | 苏州偲聚生物材料有限公司 | 多肽、包含该多肽的检测器件和检测试剂盒 |
| CN104098685B (zh) * | 2013-04-03 | 2016-03-23 | 苏州偲聚生物材料有限公司 | 多肽、包含该多肽的检测器件和检测试剂盒 |
| AR095882A1 (es) * | 2013-04-22 | 2015-11-18 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9 |
| GB2514591A (en) | 2013-05-30 | 2014-12-03 | Mologen Ag | Predictive biomarker for cancer therapy |
| AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
| JP6527516B2 (ja) | 2013-12-03 | 2019-06-05 | ノースウェスタン ユニバーシティ | リポソーム粒子、前述のものを作製する方法及びその使用 |
| AU2015269412B2 (en) | 2014-06-04 | 2020-03-12 | Exicure Operating Company | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
| WO2016028940A1 (en) | 2014-08-19 | 2016-02-25 | Northwestern University | Protein/oligonucleotide core-shell nanoparticle therapeutics |
| CA2963931A1 (en) | 2014-10-06 | 2016-04-14 | Exicure, Inc. | Anti-tnf compounds |
| US9688993B2 (en) | 2015-02-13 | 2017-06-27 | Idera Pharmaceuticals, Inc. | Toll-like receptor 9 antagonist and methods of use thereof |
| WO2016149323A1 (en) * | 2015-03-16 | 2016-09-22 | Exicure, Inc. | Immunomodulatory spherical nucleic acids |
| CN105541947A (zh) * | 2016-01-11 | 2016-05-04 | 中国人民解放军第三军医大学第一附属医院 | 拮抗tlr7/8及tlr9活化的药物分子及用途 |
| CN105597079A (zh) * | 2016-01-11 | 2016-05-25 | 中国人民解放军第三军医大学第一附属医院 | 用于治疗银屑病的药物 |
| US11339396B2 (en) | 2016-06-08 | 2022-05-24 | President And Fellows Of Harvard College | Engineered viral vector reduces induction of inflammatory and immune responses |
| CN109790220A (zh) | 2016-08-25 | 2019-05-21 | 豪夫迈·罗氏有限公司 | 与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药 |
| CN110072553B (zh) | 2016-12-22 | 2023-09-15 | 豪夫迈·罗氏有限公司 | 在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗 |
| US20180325931A1 (en) | 2017-01-21 | 2018-11-15 | Ningbo Zhiming Biotechnology Co., Ltd. | Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome |
| JP2020526558A (ja) | 2017-07-13 | 2020-08-31 | ノースウェスタン ユニバーシティ | オリゴヌクレオチド官能化金属有機構造体ナノ粒子を調製するための一般的かつ直接的な方法 |
| AU2018364542A1 (en) | 2017-11-08 | 2020-04-16 | President And Fellows Of Harvard College | Compositions and methods for inhibiting viral vector-induced inflammatory responses |
| WO2020146477A1 (en) * | 2019-01-08 | 2020-07-16 | Avogadro Development Corp. | Treatment of fatty liver disease |
| US12319711B2 (en) | 2019-09-20 | 2025-06-03 | Northwestern University | Spherical nucleic acids with tailored and active protein coronae |
| US12378560B2 (en) | 2019-10-29 | 2025-08-05 | Northwestern University | Sequence multiplicity within spherical nucleic acids |
| US20240384268A1 (en) * | 2021-04-08 | 2024-11-21 | Hudson Institute of Medical Research | Oligonucleotides |
| JP2024523466A (ja) * | 2021-06-22 | 2024-06-28 | ユニバーシティー オブ マサチューセッツ | ＩＦＮ－γシグナル伝達経路の調節のためのオリゴヌクレオチド |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPO203996A0 (en) | 1996-08-30 | 1996-09-26 | Novogen Research Pty Ltd | Therapeutic uses |
| US6426334B1 (en) | 1997-04-30 | 2002-07-30 | Hybridon, Inc. | Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal |
| DK1200580T3 (da) | 1999-08-13 | 2005-04-11 | Hybridon Inc | Modulering af oligonukleotid-CpG-medieret immunstimulering ved positionel modifikation |
| US6899891B2 (en) | 1999-12-16 | 2005-05-31 | Harry J. Siskind | Nutritional composition, methods of producing said composition and methods of using said composition |
| DE60132170T2 (de) | 2000-01-26 | 2008-12-18 | Idera Pharmaceuticals, Inc., Cambridge | MODULIERUNG DER DURCH CpG-OLIGONUKLEOTIDE VERURSACHTEN IMMUNSTIMULIERUNG DURCH POSITIONSBEDINGTE VERÄNDERUNG VON NUKLEOSIDEN |
| AU5736601A (en) | 2000-05-01 | 2001-11-12 | Hybridon Inc | Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides |
| US7105495B2 (en) | 2001-04-30 | 2006-09-12 | Idera Pharmaceuticals, Inc. | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
| US7276489B2 (en) | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
| WO2003103586A2 (en) | 2002-06-05 | 2003-12-18 | Coley Pharmaceutical Group, Inc. | Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids |
| US20050239733A1 (en) | 2003-10-31 | 2005-10-27 | Coley Pharmaceutical Gmbh | Sequence requirements for inhibitory oligonucleotides |
| GB0329146D0 (en) | 2003-12-16 | 2004-01-21 | Glaxosmithkline Biolog Sa | Vaccine |
| JP2008514187A (ja) | 2004-09-01 | 2008-05-08 | ダイナバックス テクノロジーズ コーポレイション | 先天性免疫応答及び自己免疫疾患の阻害法及び阻害用組成物 |
| US20110070575A1 (en) | 2004-12-08 | 2011-03-24 | Coley Pharmaceutical Group, Inc. | Immunomodulatory Compositions, Combinations and Methods |
| EP1836218A2 (en) | 2004-12-17 | 2007-09-26 | Dynavax Technologies Corporation | Methods and compositions for induction or promotion of immune tolerance |
| US8426375B2 (en) | 2005-10-12 | 2013-04-23 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response |
| US8399423B2 (en) | 2005-10-12 | 2013-03-19 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response |
| US8383598B2 (en) | 2005-10-12 | 2013-02-26 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response |
| ES2544877T3 (es) | 2005-10-12 | 2015-09-04 | Idera Pharmaceuticals | Compuestos oligonucleótidos inmuno reguladores (IRO) para modular la respuesta inmune basada en receptor semejante a Toll |
| PL1957647T3 (pl) * | 2005-11-25 | 2015-07-31 | Zoetis Belgium S A | Oligorybonukleotydy immunostymulujące |
| US8377898B2 (en) | 2006-10-12 | 2013-02-19 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response |
| MX2010001785A (es) | 2007-08-15 | 2010-03-10 | Idera Pharmaceuticals Inc | Moduladores de receptores tipo larga distancia. |
| CA2703931C (en) | 2007-10-26 | 2016-08-16 | Dynavax Technologies Corporation | Methods and compositions for inhibition of immune responses and autoimmunity |
| WO2009058361A1 (en) * | 2007-10-31 | 2009-05-07 | Dynavax Technologies Corp. | Inhibition of type i ifn production |
| WO2009154609A1 (en) | 2008-06-17 | 2009-12-23 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response |
| AU2009302468A1 (en) | 2008-10-06 | 2010-04-15 | Idera Pharmaceuticals, Inc. | Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto |
| US8987221B2 (en) | 2009-06-01 | 2015-03-24 | Idera Pharmaceuticals, Inc. | Potentiation of autoimmune and inflammatory disease treatments by immune regulatory oligonucleotide (IRO) antagonists of TLR7 and TLR9 |
| WO2011005942A2 (en) | 2009-07-08 | 2011-01-13 | Idera Pharmaceuticals, Inc. | Oligonucleotide-based compounds as inhibitors of toll-like receptors |
| KR101985382B1 (ko) * | 2010-11-19 | 2019-06-03 | 이데라 파마슈티칼즈, 인코포레이티드 | 톨-유사 수용체 기반 면역 반응을 조절하기 위한 면역 조절 올리고뉴클레오타이드(ｉｒｏ) 화합물 |
-
2011
- 2011-11-18 KR KR1020137015717A patent/KR101985382B1/ko not_active Expired - Fee Related
- 2011-11-18 JP JP2013540054A patent/JP5813778B2/ja not_active Expired - Fee Related
- 2011-11-18 CA CA2817891A patent/CA2817891C/en active Active
- 2011-11-18 MX MX2013005667A patent/MX340363B/es active IP Right Grant
- 2011-11-18 EP EP17166068.1A patent/EP3213770B1/en active Active
- 2011-11-18 ES ES11841875T patent/ES2697606T3/es active Active
- 2011-11-18 EP EP11841875.5A patent/EP2640420B1/en active Active
- 2011-11-18 CN CN201710061331.XA patent/CN107012149A/zh active Pending
- 2011-11-18 KR KR1020197015310A patent/KR102100110B1/ko not_active Expired - Fee Related
- 2011-11-18 CN CN2011800558686A patent/CN103415302A/zh active Pending
- 2011-11-18 US US13/299,555 patent/US8486908B2/en not_active Expired - Fee Related
- 2011-11-18 AU AU2011329668A patent/AU2011329668B2/en not_active Ceased
- 2011-11-18 WO PCT/US2011/061412 patent/WO2012068470A2/en not_active Ceased
-
2013
- 2013-05-30 US US13/905,242 patent/US9096858B2/en active Active
-
2015
- 2015-07-06 US US14/791,749 patent/US9540651B2/en not_active Expired - Fee Related
-
2016
- 2016-10-26 AU AU2016250372A patent/AU2016250372B2/en not_active Ceased
- 2016-12-01 US US15/366,509 patent/US20170233741A1/en not_active Abandoned
-
2017
- 2017-10-06 US US15/726,805 patent/US20180023085A1/en not_active Abandoned
-
2018
- 2018-07-04 AU AU2018204878A patent/AU2018204878A1/en not_active Abandoned
-
2020
- 2020-04-29 AU AU2020202827A patent/AU2020202827B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013544816A5 (https=) | ||
| US12129469B2 (en) | Modified short interfering nucleic acid (siNA) molecules and uses thereof | |
| US11707480B2 (en) | Highly active compounds against COVID-19 | |
| US11472826B2 (en) | Acyclic antivirals | |
| US9133458B2 (en) | Methods for the treatment of hepatitis B and hepatitis D infections | |
| Patel et al. | Novel drugs targeting Toll-like receptors for antiviral therapy | |
| ES3050007T3 (en) | Oligomers and oligomer conjugates | |
| CA2879066C (en) | Chiral nucleic acid adjuvant | |
| US20170016000A1 (en) | Compositions and agents against hepatitis b virus and uses thereof | |
| Gane | Future anti‐HBV strategies | |
| JP2020176156A (ja) | Ｔｏｌｌ様受容体モジュレーターの固体形態 | |
| Tao et al. | Present and future therapies for chronic hepatitis B | |
| AU2017326372B2 (en) | Modified oligonucleotides and methods of use | |
| JP2017538679A5 (https=) | ||
| TW200914033A (en) | Combination motif immune stimulatory oligonucleotides with improved activity | |
| JP2015528449A5 (https=) | ||
| JP2012528867A (ja) | Ｔｌｒ７およびｔｌｒ９の免疫調節オリゴヌクレオチド（ｉｒｏ）アンタゴニストによる自己免疫および炎症性疾患治療の強化 | |
| US11685921B2 (en) | Molecules and agents for treating hepatitis B virus | |
| US10273484B2 (en) | Double-stranded RNA conjugates and their use | |
| JP2016510213A5 (https=) | ||
| WO2017173334A1 (en) | Fc receptor-mediated drug delivery | |
| US9872895B2 (en) | TLR5 ligands, therapeutic methods, and compositions related thereto | |
| JP2023527525A (ja) | インターフェロン誘導オリゴヌクレオチド二重鎖および使用方法 | |
| US20240182898A1 (en) | ENHANCED OLIGONUCLEOTIDES FOR INHIBITING RTELl EXPRESSION | |
| US20240254485A1 (en) | Sirnas targeting slc10a1 transcripts, compositions and uses thereof |